B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.
B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.